Abstract
BackgroundProstate-specific membrane antigen (PSMA) is frequently overexpressed and upregulated in prostate cancer. To date, various 18F- and 68Ga-labeled urea-based radiotracers for PET imaging of PSMA have been developed and entered clinical trials. Here, we describe an automated synthesis of [18F]DCFPyL via direct radiofluorination and validation in preclinical models of prostate cancer.Methods[18F]DCFPyL was synthesized via direct nucleophilic heteroaromatic substitution reaction in a single reactor TRACERlab FXFN automated synthesis unit. Radiopharmacological evaluation of [18F]DCFPyL involved internalization experiments, dynamic PET imaging in LNCaP (PSMA+) and PC3 (PSMA−) tumor-bearing BALB/c nude mice, biodistribution studies, and metabolic profiling. In addition, reversible two-tissue compartmental model analysis was used to quantify pharmacokinetics of [18F]DCFPyL in LNCaP and PC3 tumor models.ResultsAutomated radiosynthesis afforded radiotracer [18F]DCFPyL in decay-corrected radiochemical yields of 23 ± 5 % (n = 10) within 55 min, including HPLC purification. Dynamic PET analysis revealed rapid and high uptake of radioactivity (SUV5min 0.95) in LNCaP tumors which increased over time (SUV60min 1.1). Radioactivity uptake in LNCaP tumors was blocked in the presence of nonradioactive DCFPyL (SUV60min 0.22). The muscle as reference tissue showed rapid and continuous clearance over time (SUV60min 0.06). Fast blood clearance of radioactivity resulted in tumor-blood ratios of 1.0 after 10 min and 8.3 after 60 min. PC3 tumors also showed continuous clearance of radioactivity over time (SUV60min 0.11). Kinetic analysis of PET data revealed the two-tissue compartmental model as best fit with K1 = 0.12, k2 = 0.18, k3 = 0.08, and k4 = 0.004 min−1, confirming molecular trapping of [18F]DCFPyL in PSMA+ LNCaP cells.Conclusions[18F]DCFPyL can be prepared for clinical applications simply and in good radiochemical yields via a direct radiofluorination synthesis route in a single reactor automated synthesis unit. Radiopharmacological evaluation of [18F]DCFPyL confirmed high PSMA-mediated tumor uptake combined with superior clearance parameters. Compartmental model analysis points to a two-step molecular trapping mechanism based on PSMA binding and subsequent internalization leading to retention of radioactivity in PSMA+ LNCaP tumors.Electronic supplementary materialThe online version of this article (doi:10.1186/s13550-016-0195-6) contains supplementary material, which is available to authorized users.
Highlights
Prostate-specific membrane antigen (PSMA) is frequently overexpressed and upregulated in prostate cancer
The following important results emerged from this study: [1] radiotracer [18F]DCFPyL can be prepared in good radiochemical yields suitable for clinical applications via a direct radiofluorination synthesis route in an automated GE TRACERlabTM FXFN synthesis unit; [2] radiopharmacological profile of [18F]DCFPyL prepared in an automated synthesis unit (ASU) via direct radiofluorination agrees as expected with previously published work such as high specific uptake and retention in PSMA+ tumors, very high metabolic stability, and high bioavailability in vivo
We have developed an automated synthesis for radiotracer [18F]DCFPyL based on a direct radiofluorination synthesis route
Summary
Prostate-specific membrane antigen (PSMA) is frequently overexpressed and upregulated in prostate cancer. Prostate cancer is among the most common malignancy in men in Western countries and accounts for the fifth leading cause of cancer-related death in men [1]. This situation clearly underscores prostate cancer as a highly frequent but still unmet medical challenge which continues to be the target of a significant proportion of current clinical research, including to a large extent the development of novel radiotracers for positron emission tomography (PET) imaging of prostate cancer [2, 3]. The aforementioned limitations of [18F]FDG-PET in connection with the importance of prostate cancer as a significant unmet clinical need drive current developments towards targeted molecular imaging of prostate cancer. PSMA is a highly promising biomarker for targeted prostate cancer imaging due to its elevated expression and up-regulation in poorly differentiated, metastatic, and androgen-independent carcinomas
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.